Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$0.75
-$0.01(-1.32%)
At close: 4:00 PM EDT
$0.75
-$0.01(-1.32%)
Day’s Range― - ―
52-Week Range$0.56 - $4.31
Previous Close$2.13
Volume48.12K
Average Volume (3M)206.82K
Market Cap
$20.28M
Enterprise Value$116.37
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta3.17
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Allogeneic PlatformCelularity’s core placental-derived allogeneic cell and biomaterial platform is a durable competitive asset: it supports multiple therapeutic modalities (NK, T-cell, regenerative biomaterials) and internal manufacturing/sourcing advantages, enabling reuse across oncology and regenerative indications and lowering single-product binary risk.
Diverse Commercial Monetization ModelThe company’s multi-pronged revenue strategy (collaborations, licensing, tissue services, and eventual product sales) provides structural optionality. This diversity can generate near-term non‑clinical revenue streams and milestone payments that de-risk reliance on a single regulatory approval for long-term cash generation.
Improving Cash Burn TrendOperating cash outflows and free‑cash‑flow losses have meaningfully narrowed versus earlier years, indicating management has reduced burn. Sustained lower burn extends runway, reduces near‑term financing dependency, and makes executing partnerships or staged development financing more feasible over the coming months.
Bears Say
Negative Equity / High LeverageNegative shareholders’ equity and sustained debt materially impair financial flexibility. This structural balance‑sheet weakness raises refinancing and dilution risk, constrains negotiating leverage with partners or lenders, and can limit the firm’s ability to fund clinical programs without dilutive or costly capital solutions.
Declining Revenue & Sustained LossesA sharp revenue contraction together with persistent operating losses indicates the business has not reached scalable, margin‑generating operations. Structurally, falling top‑line and recurring negative EBIT reduce internal funding capacity and make long‑term commercialization and sustained margin recovery more challenging.
Listing Risk And Financing StrainRepeated Nasdaq listing deficiency notices plus reliance on a secured, related‑party short‑term loan reflect structural financing stress and governance risks. Ongoing listing risk can constrain capital access and partner confidence, while insider financing tied to company collateral may signal limited third‑party funding options.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.56 and its highest was $4.31 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $20.28M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 233 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Celularity
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
14.57% Insiders
2.63% Mutual Funds
0.23% Other Institutional Investors
80.42% Public Companies and
Individual Investors